Diabetes mellitus is a debilitating chronic disease that places a large financial burden on the US healthcare system. In 2012 alone, diabetes accounted for \$176 billion in direct medical costs and \$69 billion in reduced productivity \[[@B1]\]. One manner in which such costs are generated is through the management of chronic wounds that arise and persist in diabetics due to impairment of the normal wound healing process.

Macrophages are key mediators of proper wound healing that exist in multiple phenotypes with diverse functionality \[[@B2]\]. Normal wound healing begins with an early inflammatory stage dominated by the pro-inflammatory M1 macrophage. This macrophage phenotype secretes pro-inflammatory cytokines and serves to clear pathogens and damaged tissue. Over time, a phenotypic switch occurs toward the M2 phenotype that promotes wound healing and decreases inflammation. Recently, Nassiri *et al*. reported that the relative level of inflammation of a wound can be monitored by measuring a set of mRNA associated with the M1 (*VEGF*, *CCR7*, *IL1β*, *CD80*) and M2 (*MRC1*, *TIMP3*, *PDGF*) macrophage phenotypes and calculating a M1:M2 score \[[@B3]\]. In diabetic subjects, the ratio of M1 (pro-inflammatory) to M2 (anti-inflammatory) macrophages is increased \[[@B4]\]. As a result, the proliferative phase is impeded in diabetic subjects, delaying wound healing.

Urinary bladder matrix (UBM) is an extracellular matrix scaffold derived from the mucosa of porcine urinary bladder that provides a structural scaffold for cell migration, adhesion and proliferation \[[@B8]\]. UBM has been shown to foster a proportional increase in M2 macrophages both *in vitro* and in animal models \[[@B7],[@B11],[@B12]\]. As such, macrophages in diabetic patients may reverse their abnormal phenotypic behavior, thereby promoting a normal healing response.

The use of UBM for the management of chronic wounds in diabetic patients has been described in numerous case reports and two prospective randomized trials with promising results \[[@B13]\]. The aim of this study was to test the ability of UBM to affect macrophage phenotype-related gene expression and the resultant M1:M2 score in the wounds of diabetic subjects compared to that observed in nondiabetic patients. Using wound debridement samples and the M1:M2 score, we examined M1:M2 content pre- and post-UBM application in diabetic and nondiabetic patients. These data provide initial mechanistic insight underlying the ability of UBM to facilitate proper wound healing in the diabetic setting.

Patients & methods {#S0001}
==================

Patient population & wound debridement {#S0002}
--------------------------------------

This single center, prospective case--control study was conducted at University Medical Center New Orleans (UMCNO) from November 2015 to April 2017. Wound measurement, debridement and UBM application were performed by a single general surgeon physician. Included participants were English speaking consecutive patients aged 18--65 years with open wounds that had not previously been treated with a biologically derived scaffold referred to the UMCNO Wound Care Clinic for wound management after the study start date who consented to receiving the UBM product. Exclusion criteria were clinically infected wounds (i.e., wounds demonstrating Galen\'s dolor, calor, tumor and rubor), concurrent hyperbaric therapy, non-English speaking patients, prior therapy of the target wound with biologically derived products (i.e., UBM, Oasis, Primatrix, etc.) and patients \<18 or \>65 years. Informed consent was obtained from each patient and the study was approved by both the Louisiana State University (LSU) Health New Orleans Health Sciences Center and the UMCNO Institutional Review Boards. All patients provided written informed consent to participate in the study.

Patients were referred to the UMCNO Wound Care Clinic from inpatient discharge referrals with initial accrual of 20 patients (10 diabetic and 10 nondiabetic). Two patients, however, chose to withdraw and these data were not included. Wound debridement samples along with appropriate medical history were obtained from nondiabetic and diabetic patients, immediately prior to application of UBM. Upon completion of debridement, Cytal^®^ Wound Matrix 1-Layer (single layer sheet, ACell, Inc., MD, USA), MicroMatrix^®^ (particulate, ACell, Inc.) or both UBM products were applied throughout each wound according to depth and size, and they were covered with a water-based lubricant, nonadherent dressing and final securing over dressing. A second wound debridement sample was obtained 7--14 days after UBM application. The second sample was not obtained from two nondiabetic patients due to failure to collect the sample and one diabetic patient due to wound healing. Wound area reduction was measured at the time of the second debridement sample collection. Pretreatment wound area reduction was calculated from data in the patients' medical history. The rate of wound area reduction was calculated as the percent decrease in wound size divided by the number of days between wound measurements. Hemoglobin A1c values measured pretreatment and within 3 months of the end of treatment were obtained from the medical records of a subset of the diabetic patients (n = 6).

RNA measurement {#S0003}
---------------

Debridement samples were stored in RNAlater solution until total RNA was isolated using the Qiagen MiniKit (Qiagen, Hilden, Germany). Copies of mRNA associated with the M1 (*VEGF*, *CCR7*, *IL1β*, *CD80*) and M2 (*MRC1*, *TIMP3*, *PDGF*) macrophage phenotype were measured in the samples using droplet digital PCR (ddPCR). A one-step PCR reaction was prepared using Qiagen primers (Supplementary Table 1) coupled with Superscript reverse transcriptase (Qiagen) and the QX200 ddPCR EvaGreen Supermix (Bio-Rad, CA, USA). Reaction droplets were prepared and read using the QX200 ddPCR system.

Data analysis {#S0004}
-------------

Using the methodology of Nassiri *et al*., we calculated an M1:M2 score that is higher for M1 macrophages and lower for M2 macrophages, and that has been shown to increase in nonhealing wounds and decrease in healing wounds \[[@B3],[@B17]\]. Prior to calculating the M1:M2 score, the gene expression data were normalized to prevent bias due to differing baseline gene expression. The copy numbers of each individual mRNA were normalized by dividing them by the median of copy number for that mRNA. The M1:M2 score was calculated as the ratio of the sum of the normalized values of M1 associated mRNAs to the sum of the normalized values for the M2 associated mRNA using the following equation:

where ![](rme-14-269-e2.jpg)

Statistical analysis {#S0005}
--------------------

Comparison of continuous variable means between nondiabetic and diabetic patients was performed using paired Student\'s t-test. Differences in categorical variables were determined using χ^2^ analysis. A p \< 0.05 was considered statistically significant.

Data availability {#S0006}
-----------------

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Results {#S0007}
=======

Patient population {#S0008}
------------------

A total of nine diabetic and nine nondiabetic patient samples were analyzed. Within this group, mean patient age was 51.8 ± 2.6 years (range: 20--62) and 50% (n = 9) were male. Mean BMI was 35.1 ± 1.8 lb/in^2^. Hemoglobin A1c values in the diabetic patients demonstrated improved glucose control during the treatment period compared with prior to treatment with mean values of 8.0 ± 0.7 versus 10.3 ± 1.0, respectively. The average initial wound area was 6.5 ± 1.7 cm^2^. More than 70% (n = 13) of the patients in this study were smokers. No significant differences were found in age, BMI, initial wound area or smoking status between the diabetic and nondiabetic groups ([Table 1](#T1){ref-type="table"}). The duration of wounds prior to treatment is listed in [Table 2](#T2){ref-type="table"}. Wounds were located on the foot (n = 9), abdomen (n = 5), hand (n = 2), hip, head and thigh. Most wounds were those that developed after a patient had undergone an operative procedure to treat a surgical condition (n = 12). Application of UBM was associated with significant wound size reduction in both patient groups with a 35% ± 14% reduction in the diabetic and a 43% ± 18% reduction in the nondiabetic patients (p \< 0.05, [Figure 1](#F0001){ref-type="fig"}A), with all but one diabetic patient exhibiting some magnitude of wound closure. A significant increase in the rate of wound area reduction compared with pretreatment was also observed in both patient groups ([Figure 1](#F0001){ref-type="fig"}B; p \< 0.05). One diabetic patient\'s wound fully healed prior to the follow-up visit and therefore only a pretreatment sample was obtained.

###### **Demographic and clinical variables of study patients.**

  **Characteristics**         **All patients**   **Nondiabetic (n = 9)**   **Diabetic (n = 9)**   **p-value**
  --------------------------- ------------------ ------------------------- ---------------------- -------------
  Age, years                  51.8 ± 2.6         46.8 ± 4.7                55.8 ± 1.3             0.13
                                                                                                  
  BMI, lb/in^2^               35.1 ± 1.8         32.5 ± 2.4                37.6 ± 2.6             0.18
                                                                                                  
  Initial wound area, cm^2^   6.5 ± 1.7          3.8 ± 1.2                 8.3 ± 2.9              0.25
                                                                                                  
  Male sex                    9 (50)             5 (56)                    4 (44)                 0.64
                                                                                                  
  Smoker                      13 (72)            7 (39)                    6 (33)                 1

###### **Wound characteristics.**

  **Patient**   **Diabetic**   **Etiology**           **Location**   **Duration prior to treatment (days)**
  ------------- -------------- ---------------------- -------------- ----------------------------------------
  1             N              Surgical               Abdomen        58
                                                                     
  2             Y              Surgical               Foot           63
                                                                     
  3             N              Surgical               Hand           14
                                                                     
  4             Y              Diabetic foot ulcer    Foot           219
                                                                     
  5             N              Surgical               Foot           107
                                                                     
  6             Y              Surgical               Foot           28
                                                                     
  7             N              Surgical               Hip            12
                                                                     
  8             Y              Surgical               Foot           59
                                                                     
  9             N              Venous stasis ulcer    Foot           292
                                                                     
  10            Y              Surgical               Abdomen        14
                                                                     
  11            Y              Surgical               Abdomen        21
                                                                     
  12            Y              Surgical               Abdomen        51
                                                                     
  13            N              Avulsion               Foot           76
                                                                     
  14            Y              Traumatic amputation   Hand           67
                                                                     
  15            Y              Diabetic foot ulcer    Foot           636
                                                                     
  16            N              Surgical               Back           16
                                                                     
  17            N              Laceration             Head           45
                                                                     
  18            N              Surgical               Thigh          35

![**Comparison of wound area reduction in diabetic and nondiabetic patients.**\
**(A)** Similar wound area reduction was observed in the diabetic and nondiabetic patient groups. **(B)** UBM was associated with a significant increase in the rate of wound area closure compared with pretreatment in both the diabetic and nondiabetic patient groups. Bar indicates p \< 0.05.\
UBM: Urinary bladder matrix.](rme-14-269-g1){#F0001}

Macrophage phenotype associated mRNA {#S0009}
------------------------------------

Wound healing is associated with a transition of macrophages from the M1 to M2 phenotype, and wounds in diabetic patients are known to exhibit elevated levels of M1 macrophages compared with M2. To assess the character of the inflammation in the wounds, we measured a set of mRNAs associated with the M1 (*IL1β*, *CD80*, *CCR7* and *VEGF*) and M2 (*PDGF*, *MRC1* and *TIMP3*) phenotypes pre- and post-treatment. In the total population, significant increases in *VEGF*, *MRC1* and *TIMP3* were observed following UBM treatment ([Figure 2](#F0002){ref-type="fig"}A). Similar trends were observed in the diabetic and nondiabetic groups individually, although significance was only found in *TIMP3* in the nondiabetic population ([Figure 2](#F0002){ref-type="fig"}B) and *VEGF* in the diabetic population ([Figure 2](#F0002){ref-type="fig"}C).

![**Expression of genes associated with macrophage phenotype in pre- and post-treatment wound debridement samples.**\
**(A)** All patients; **(B)** nondiabetic patients; **(C)** diabetic patients. Bar indicates p \< 0.05.](rme-14-269-g2){#F0002}

M1:M2 scores {#S0010}
------------

A score based on the ratio of the expression of the genes associated with the macrophage phenotypes (M1:M2 score) has been previously demonstrated to be indicative of wound healing and the character of the wound inflammation \[[@B3],[@B17]\]. The diabetic patients in this study exhibited a significantly higher M1:M2 score pretreatment compared with post-treatment (4.42 ± 0.58 vs 2.075 ± 0.94; p \< 0.05; [Figure 3](#F0003){ref-type="fig"}A). The M1:M2 score was reduced to similar levels in both diabetic and nondiabetic patients following UBM treatment (2.06 ± 0.74 vs 1.67 ± 0.75; p = 0.36). This represents a significantly greater decrease in the magnitude of change in the individual M1:M2 scores in the diabetic versus nondiabetic patients (2.89 ± 0.68 vs 0.66 ± 0.53; p \< 0.05). Additionally, the magnitude of the decrease in the M1:M2 score correlated with the magnitude of the rate of wound area reduction (R^2^ = 0.36; p = 0.04; [Figure 3](#F0003){ref-type="fig"}B). These data suggest UBM treatment is effective at restoring the state of inflammation in the wounds of diabetic patients to that of nondiabetic patients.

![**Comparison of M1:M2 score between groups and to the rate of wound area reduction.**\
**(A)** The M1:M2 score in wound debridement samples of diabetic patients is reduced to levels similar to that of nondiabetic patients following treatment with UBM. Bar indicates p \< 0.05. **(B)** The M1:M2 score correlates with the rate of wound area reduction. Dotted line indicates the 95% CI. Open symbols indicate nonsurgical wounds.\
UBM: Urinary bladder matrix.](rme-14-269-g3){#F0003}

Discussion {#S0011}
==========

In this study, we use a score to characterize the inflammation of wounds before and after treatment with UBM. Prior to treatment, the wounds of diabetic patients exhibited a significantly higher M1:M2 score, suggesting greater pro-inflammatory activity. Wounds in diabetic animal models exhibit a prolonged expression of M1 macrophage markers and suppression of M2 macrophage recruitment compare to nondiabetic animal models \[[@B18],[@B19]\]. Multiple mechanisms likely play a role in the increase in M1 macrophage polarization in diabetic patients, including diabetes-induced changes in histone methylation within bone marrow progenitor cells, loss of vascular endothelial growth factor receptor Type 1 signaling, and advanced glycation end-product activation of autophagy \[[@B20]\]. More recently, research suggests that the hyperglycemic/diabetic wound environment induces the expression of certain miRNA molecules to favor the inflammatory phenotype in macrophages \[[@B23]\]. Management of wounds with UBM achieved similar macrophage-related gene expression and M1:M2 score in both diabetic and nondiabetic patients despite the diabetic patients initially having a significantly higher M1:M2 score. Therapies that promote increased M2 or inhibit M1 macrophage polarization in the later stages of wound healing are effective at enhancing wound healing in diabetic animal models \[[@B24]\]. Similarly, decreases in the M1:M2 score are associated with appropriate wound healing \[[@B3],[@B17]\]. Thus, our data suggest that treatment of diabetic wounds with UBM is associated with a modulation of the inflammation within the wound that enables wound healing.

The mechanism through which UBM facilitates modulation of wound inflammation is likely multifaceted and needs further investigation. Separation of UBM into its soluble and structural fractions identified that the structural components promoted a reduction in macrophage phagocytic activity and an M2-like phenotype \[[@B27]\]. Seeding of macrophages onto UBM results in M2 polarization through activation of peroxisome proliferator activated receptor gamma signaling \[[@B28]\]. Dearth *et al*. demonstrated that inhibition of cyclooxygenases 1 and 2 reduced M2 polarization and inhibited the accelerated wound healing associated with UBM treatment \[[@B29]\]. A better understanding of these mechanisms and which ones predominate in the diabetic setting will allow for a better design of therapies to promote diabetic wound healing.

Diabetic patients are at high risk for chronic wounds, especially diabetic foot ulcers which have a worldwide prevalence of 6.3% \[[@B30]\]. In addition to a predilection for developing DFUs, diabetic patients are prone to developing other types of wounds that, due to impaired cellular responses to healing, can develop into chronic conditions, increasing costs. For example, Martin *et al*. demonstrated in a systematic review that diabetic patients have an associated higher risk of developing surgical site infections \[[@B31]\]. We designed this study to examine whether treatment with UBM would be associated with a restoration of the normal (nondiabetic) state of inflammation in the variety of wounds prone to poor healing in the diabetic population. UBM is a medical device that falls into the skin substitute category from an outpatient reimbursement perspective. To date, applications of UBM in the clinical domain are wide ranging, including management of burns, coverage of fasciocutaneous donor sites and as a scaffold for management of full-thickness traumatic wounds with exposed tendons or open fractures \[[@B32]\]. Most recently, a randomized controlled trial compared its use in treatment of DFU with standard therapy, suggesting it might have benefit in time-to-healing and reduction in recurrence \[[@B13]\]. Our study provides additional evidence that following treatment with UBM wounds exhibit a reduction in the level of inflammation in the wound, exhibited here by a normalization of the M1:M2 score, thereby resetting the wound environment to the 'wild-type' nondiabetic phenotype.

This study was designed to test whether treatment with UBM was associated with a restoration of a normal inflammatory state in diabetic wounds, and we acknowledge the limitations of this study. Although UBM treatment was associated with a decrease in the M1:M2 score, without longitudinal M1:M2 score data from untreated patients, we cannot rule out that the standard of care would result in a decrease in the M1:M2 score as well. Patients were not randomized nor controlled when selected for this study. We therefore cannot exclude the possibility of bias. No significant differences, however, were found in age, BMI, initial wound area or smoking status between the diabetic and nondiabetic groups, which are all known to be factors that affect wound healing. This study aimed to examine UBM treatment in the multiple types of wounds that exhibit poor healing in the diabetic population and thus included a variety of wound types. The heterogeneity of patients in this study and the variety of treatments (some required different graft sizes) inherent to wound healing studies could have had an influence on results; however, no association between the results and the etiology of the wound were observed. Thus, future studies are needed to examine UBM treatment in specific wound types. It is important to note that other cells in the wound environment may also express these genes, and so the M1:M2 score is more likely an indicator of the character of inflammation as opposed to macrophage phenotype per se. Finally, the small sample size of both groups (nine patients in each) is a limitation, as results could be skewed in one direction. Thus, further work with larger sample sizes, extended treatment times and comparisons to additional treatments are needed in order to fully elucidate the effects of UBM in the diabetic setting.

Conclusion {#S0012}
==========

UBM has the potential to restore an appropriate inflammatory state in the wounds of diabetic patients, which may facilitate a normal healing response. Treatment with UBM decreased M1:M2 scores, achieving a statistically similar score between diabetic and nondiabetic subjects post-treatment. With modifiable risk factors addressed, this study suggests that UBM may decrease time to healing in diabetic patients by allowing for mitigation of the inflammatory effects of the disease. Future studies in a large, randomized controlled trial may better clarify the abilities of UBM and its efficacy in wound healing and wound care management, especially in the setting of diabetic wounds.

Translational perspective {#S0013}
-------------------------

Impaired wound healing is common in diabetic patients, increasing the costs associated with the treatment of chronic wounds in this population. Several clinical studies report the use of UBM for the management of chronic wounds in diabetic patients has the potential to improve the time to healing and rates of recurrence \[[@B13]\]. Whether this represents a general effect of exposure to UBM common to all patients or represents a specific advantage of the use of UBM in the diabetic population remains unclear. This report demonstrates for the first time that although the wounds of diabetic patients exhibit an elevated M1:M2 score prior to treatment, application of UBM is associated with a restoration of an M1:M2 score similar to that of nondiabetic patients. Such insight provides a scientific basis for the use of UBM in the diabetic population. Future studies are needed to elucidate potential advantages in specific wound types and the effects of long-term application.

###### Executive summary

-   Application of urinary bladder matrix (UBM) was associated with significant wound size reduction in both diabetic and nondiabetic patients. UBM application was associated with significant increases in the expression of genes associated with the M1 macrophage phenotype, *VEGF* and the M2 macrophage phenotype, *MRC1* and *TIMP3*.

-   A M1:M2 score was calculated based on a set of mRNAs associated with the M1 (*IL1β*, *CD80*, *CCR7* and *VEGF*) and M2 (*PDGF*, *MRC1* and *TIMP3*) phenotypes.

-   Increased rates of wound closure during treatment correlated with decreases in the M1:M2 score pre- versus post-treatment.

-   The diabetic patients in this study exhibited a significantly higher M1:M2 score than nondiabetic patients prior to treatment.

-   Following treatment with UBM, the M1:M2 scores in the diabetic patients was similar to that of the nondiabetic patients.

-   These data suggest that application of UBM is associated with restoration of an appropriate immune response in the wounds of diabetic patients, which may facilitate a normal healing response.
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